Geographical Disparities in the Detection and Certification of Systemic Amyloidosis in Japan: A Nationwide Registry Analysis, 2015-2024.
Rural areas in Japan are missing diagnoses of a treatable blood disorder, revealing access gaps that new treatments now make urgent to fix.
Nationwide registry analysis of systemic amyloidosis detection and certification in Japan (2015-2024) demonstrates substantial geographical disparities, with rural areas showing significantly lower detection rates than major urban centers. These findings suggest systematic underdiagnosis outside specialized centers and support policy interventions to improve access to amyloidosis diagnosis, particularly given newly approved treatments such as tafamidis.
What the study was
- Study design
- nationwide registry analysis
- Population
- Systemic amyloidosis patients across Japan, 2015-2024 registry
- Category
- Public Health
- Maturity
- Validated
- Journal
- Circulation reports
Why it surfaced
Nationwide registry analysis (10 years) documenting geographic access inequity for amyloidosis diagnosis; relevant to rare disease detection policy; systemic amyloidosis has newly approved treatments (tafamidis) making early detection clinically impactful.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.